The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption Alan K. Davis, Joseph P. Barsuglia, Rafael Lancelotta, Robert M. Grant, and Elise Renn Journal of Psychopharmacology, 2018, 32, (7), 779–792. doi : 10.1177/0269881118769063 Abstract Background/Aim : 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a psychoactive compound found in several plants and in high concentrations in Bufo alvarius toad venom. Synthetic, Toad, and Plant-sourced 5-MeO-DMT are used for spiritual and recreational purposes and may have psychotherapeutic effects. However, the use of 5-MeO-DMT is not well understood. Therefore, we examined patterns of use, motivations for consumption, subjective effects, and potential benefits and consequences [...]
Lire la suiteModern Clinical Research on LSD Matthias E Liechti Neuropsychopharmacology, 2017, 42, 2114–2127. doi : 10.1038/npp.2017.86 All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left [...]
Lire la suiteCannabinoid Regulation of Fear and Anxiety : an Update Eleni P. Papagianni & Carl W. Stevenson Current Psychiatry Reports, 2019, 21, 38 doi : 10.1007/s11920-019-1026-z Abstract Purpose of Review : Anxiety- and trauma-related disorders are prevalent and debilitating mental illnesses associated with a significant socioeconomic burden. Current treatment approaches often have inadequate therapeutic responses, leading to symptom relapse. Here we review recent preclinical and clinical findings on the potential of cannabinoids as novel therapeutics for regulating fear and anxiety. Recent Findings : Evidence from preclinical studies has shown that the non-psychotropic phyto-cannabinoid cannabidiol and the endocannabinoid anandamide have acute anxiolytic effects and also regulate learned fear [...]
Lire la suitePatient Experiences of Psilocybin-Assisted Psychotherapy : An Interpretative Phenomenological Analysis Alexander B. Belser, Gabrielle Agin-Liebes, T. Cody Swift, Sara Terrana, Neşe Devenot, Harris L. Friedman, Jeffrey Guss, Anthony Bossis and Stephen Ross Journal of Humanistic Psychology, 2017, 1 –35 Doi : 10.1177/0022167817706884 journals.sagepub.com/home/jhp Abstract The psychological mechanisms of action involved in psilocybin-assisted psychotherapy are not yet well understood. Despite a resurgence of quantitative research regarding psilocybin, the current study is the first qualitative study of participant experiences in psilocybin-assisted psychotherapy. Semistructured interviews were carried out with 13 adult participants aged 22 to 69 years (M = 50 years) with clinically elevated anxiety associated with a cancer [...]
Lire la suiteEmerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L Robertshaw & Andrew D Westwell Future Medical Chemistry, 2019 Doi : 10.4155/fmc-2018-0447 C - ISSN 1756-8919 “Public and mainstream scientific perceptions of these substances are shifting, and it is not difficult to envision a future in which MDMA and psilocybin play a role in contemporary medicine.” Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a [...]
Lire la suitePsilocybin-assisted therapy for depression : How do we advance the field ? Sally E Meikle, Paul Liknaitzky, Susan L Rossell, Margaret Ross, Nigel Strauss, Neil Thomas, Greg Murray, Martin Williams, David J Castle Australian & New Zealand Journal of Psychiatry, 2019, 1–7 Doi : 10.1177/0004867419888575 Abstract In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use [...]
Lire la suitePsychedelics and music : neuroscience and therapeutic implications Frederick S. Barrett, Katrin H. Preller & Mendel Kaelen International Review of Psychiatry, 2018 https://doi.org/10.1080/09540261.2018.1484342 ABSTRACT From the beginning of therapeutic research with psychedelics, music listening has been consistently used as a method to guide or support therapeutic experiences during the acute effects of psychedelic drugs. Recent findings point to the potential of music to support meaning-making, emotionality, and mental imagery after the administration of psychedelics, and suggest that music plays an important role in facilitating positive clinical outcomes of psychedelic therapy. This review explores the history of, contemporary research on, and future directions regarding the use [...]
Lire la suiteTribune pour l’expérimentation des psychédéliques en médecine, contre la dépression, l’anxiété, les addictions et pour les soins palliatifs. Société Psychédélique Française, novembre 2019 D’après l’Organisation mondiale de la santé, une personne sur quatre dans le monde sera affectée à un moment donné de sa vie par des troubles mentaux ou neurologiques. Or, après des décennies d’oubli, nous assistons en dehors de nos frontières à un regain de la recherche clinique psychothérapeutique sur les psychédéliques et au développement de thérapies novatrices impliquant ces substances. Les psychédéliques sont des composés, issus du monde vivant ou de la chimie, provoquant des effets analogues sur le psychisme [...]
Lire la suiteChapter 8 : Pilgrimage to the Light ? On the Threshold of a Dream: Sacred Plants, Passionate Dedication to Ideals, and Healing Richard Yensen January 2015 https://www.researchgate.net/publication/282132139 The desire to incorporate ancient healing practices with sacred plants into modern medicine has been a central passion of my career as a clinician and psychedelic researcher for over 40 years. During that time Mexico has offered me friendship, collegiality, adventure, and wonder. At times I have felt when visiting first Nations in Mexico like I was stepping back into ancient times. The wonder and honor of knowing Maria Sabina, Don Ricardo, Niuweme, and other healers and [...]
Lire la suiteEmerging from the dark side : new therapeutic applications of scheduled psychoactive substances Edward James, Thomas L. Robertshaw & Andrew D. Westwell Future medicinal chemistry, February 2019 Doi : 10.4155/fmc-2018-0447 Keywords : harm reduction • healthcare • MDMA • positive psychology • psilocybin • psychoactive • psychotherapy The discovery and development of new medicines occupies years of painstaking and expensive scientific work, with multidisciplinary teams working together in the hope of developing a new chemical entity that outperforms the current standard of care within the chosen disease setting. Once optimized in the laboratory and achieving acceptable regulatory preclinical benchmarks, years of clinical evaluation are required [...]
Lire la suite